Shares of

Exact Sciences

(EXAS) - Get Report

were among the best-performing health-related stocks Monday, jumping 12% after the biotech company said its DNA-based colon-cancer screening technology performed well in a study.

The company said its stool DNA-testing technology was able to demonstrate an 88% sensitivity for cancer, with an 82% specificity. "Colonoscopy is the gold standard for colorectal cancer screening and is usually our first screening recommendation to patients," the study's lead investigator said. "However, many people are reluctant to undergo a colonoscopy. This study shows that very high sensitivity can be achieved with noninvasive, stool DNA testing." The data were presented at the annual Digestive Disease Week conference on Sunday.

"With sensitivity for colorectal cancer approaching 90%, we believe that stool DNA testing and colonoscopy could be a powerful one-two punch in the quest to get more people screened and to reduce colon cancer mortality," Exact Sciences said. Shares were trading up 24 cents to $2.48.

Quest Diagnostics

(DGX) - Get Report

fell 1% after the company said it received a subpoena from the California attorney general's office. The subpoena, the company said, requests documents relating to billings to MediCal, the state's Medicaid program. The subpoena covers documents over three to 10 years. The company said it plans to cooperate with the attorney general's office. Shares were down 55 cents to $56.98.

Shares of

Adventrx Pharmaceuticals

(ANX)

rose 6% after the company withdrew a secondary stock offering and said it received clearance to initiate a Phase III trial for CoFactor, a drug designed to improve the efficacy and safety of a widely used chemotherapy agent.

The company said that market conditions forced it to shelf its stock offering. The company had planned to sell some 15.5 million shares of stock.

As for the Phase III trial of CoFactor, Adventrx said it reached an agreement with the

Food and Drug Administration

over the design of the trial's protocol. The agreement means that Adventrx remains on track to launch the trial during the second quarter, the company said. Shares were trading up 17 cents to $4.37.

Oscient Pharmaceuticals

(OSCI)

rose 8% after the company named Philippe Maitre as its new chief financial officer. Maitre will replace Stephen Cohen, who is retiring after five years as CFO. "A veteran of the pharmaceutical industry, Philippe was the CFO of a leading publicly-traded contract research organization and deputy CFO for a large pharmaceutical company," Oscient said in a statement. Shares were trading up 10 cents to $1.35.

Other health care volume movers included

Pfizer

(PFE) - Get Report

, up 24 cents to $24.06;

Boston Scientific

(BSX) - Get Report

, down 53 cents to $19.62;

Elan

(ELN)

, down 36 cents to $17.61;

UnitedHealth Group

(UNH) - Get Report

, down 72 cents to $43.70;

Johnson & Johnson

(JNJ) - Get Report

, unchanged at $59.90;

Amgen

(AMGN) - Get Report

, up 34 cents to $68.03;

Schering-Plough

( SGP), down 16 cents to $19.07;

Teva Pharmaceutical

(TEVA) - Get Report

, down 40 cents to $36.56;

Medtronic

(MDT) - Get Report

, down 72 cents to $48.58; and

Aetna

(AET)

, down 55 cents to $39.70.